undamentalytics Newsletter
Sign in

Autolus Therapeutics plc balance sheet

At the end of fiscal 2025, Autolus Therapeutics plc had total assets of $589m, total liabilities of $411m and shareholders' equity of $178m. It held $104m in cash against $0 of debt: net cash of $104m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Sept 20162017Sept 20172018Sept 20182019Dec 20192023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents———211240227104171
Receivables————002444
Inventory————043333
Total current assets—142259249275661436336
Total assets—149273304375783589493
Accounts payable—2310231
Deferred revenue (current)————04——
Total current liabilities—5172545617369
Long-term debt—100————
Total debt01000000
Total liabilities—61849264355411418
Shareholders' equity3114325525511142717875
Net debt (negative = net cash)———−211−240−227−104−171

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AUTL vs RCUSAUTL vs SPRYAUTL vs MESO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Autolus Therapeutics plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Autolus Therapeutics plc.